Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)
Efficacy and Safety of Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke: A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Trial
Beijing Tiantan Hospital
1,380 participants
Jan 11, 2024
INTERVENTIONAL
Conditions
Summary
Shuxuening injection is a multi-target neuroprotective agent, it is expected to play a neuroprotective role on the basis of intravenous thrombolysis therapy. The primary purpose of this multicenter, randomized, double-blind, placebo-parallel controlled trial is to evaluate the efficacy and safety of Shuxuening injection in the treatment with intravenous thrombolysis in patients with ischemic stroke.
Eligibility
Inclusion Criteria6
- Age 18 or older;
- Diagnosed with acute ischemic stroke;
- Within 6 hours of onset;
- Having received or plan to undergo intravenous thrombolytic therapy;
- NIHISS score of 4 to 25 points at enrollment;
- Signed informed consent.
Exclusion Criteria9
- mRS score greater than 1 point before the onset;
- Receiving neuroprotective agents, such as edaravone, edaravone dextrocamphorol, butylphthalein, etc. after the onset;
- Bleeding or other pathological brain disorders, such as vascular malformations, tumors, abscesses, or other common non-ischemic brain diseases (such as multiple sclerosis), detected by CT/MRI;
- History of clotting disorders, systemic bleeding, thrombocytopenia, or neutropenia;
- Severe hepatic or renal insufficiency (severe hepatic insufficiency refers to the ALT or AST levels above 3 times the upper limit of normal; severe renal insufficiency refers to the creatinine levels above 2 times the upper limit of normal);
- Allergic to Shuxuening injection or preparations containing ginkgo biloba (ginkgo biloba extract);
- Women who are pregnant or breastfeeding, and women of childbearing age who have a negative pregnancy test but refuse to take effective contraceptive measures;
- Participation in another clinical trial with an experimental product during the last 30 days;
- Other participants deemed unsuitable for participation in this study by the investigator.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Receiving 20 ml Shuxuening injection plus 250ml 0.9% sodium chloride injection, intravenous drip once a day, for 10-14 days
Receiving 20 ml placebo Shuxuening injection plus 250ml 0.9% sodium chloride injection, intravenous drip once a day, for 10-14 days.
Locations(82)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06157502